Urinary Gm2 Activator Protein As a Marker of Acute Renal Failure Or the Risk of Developing Acute Renal Failure

The invention relates to a method of determining the risk of developing acute renal failure (ARF) in an individual, or of determining an ARF, and a method of predicting the progression of an ARF, by detecting and/or quantifying the protein Ganglioside GM2 Activator Protein (GM2AP). The failure can be due to the administration of at least one nephrotoxic agent, wherein the nephrotoxic agent can be an aminoglycoside antibiotic as for example gentamicin.

Attached files:
WO 2010136059.jpg

Patents:
WO 2,010,136,059

Inventor(s): QUIROS LUIS YAREMI [ES]; FERREIRA REDONDO LAURA [ES]; SANCHO MARTINEZ SANDRA MARIA [ES]; GONZALEZ DE BUITRAGO ARRIERO JOSE MANUE

Type of Offer: Sale

Contact Patent Owner or Broker


Next Patent »
« More Medical Patents

Share on      

CrowdSell Your Patent